Response to “No Increased Risk of Breast or Gynecologic Malignancies in Women Exposed to Spironolactone for Dermatologic Conditions: A Retrospective Cohort Study”

Author Type(s)

Student

Document Type

Letter to the Editor

Publication Date

12-1-2024

DOI

10.1016/j.jaad.2024.05.105

Journal Title

Journal of the American Academy of Dermatology

Keywords

breast cancer, malignancy, risk assessment, spironolactone

Disciplines

Medicine and Health Sciences

Share

COinS